A Phase 3 interventional study of Esreboxetine and Placebo in Fibromyalgia, sponsored by Pfizer. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-29.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Fibromyalgia by Pfizer — none open to participants now, none under way, none of them phase 3. Fibromyalgia · Pfizer.
Among the 12 studies in Fibromyalgia by Pfizer, this one is the 12th largest by enrollment, is one of 2 that started in 2009, is one of 5 in phase 3, and was the 10th registered.
1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →None of the 12 studies in Fibromyalgia by Pfizer is open now. The open studies under Fibromyalgia, anywhere →
Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 7
First in 2006; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 283 across the 12 interventional studies. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Fibromyalgia by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The hypothesis of Study A6061054 is to demonstrate superiority of efficacy of esreboxetine at 3 and 6 months compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Esreboxetine
Drug: Placebo
Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
Film coated tablets (0 mg esreboxetine), once daily for 6 months
Change from baseline to 3 and 6 months in the mean daily pain rating score measured by the 11 point pain intensity Numerical Rating Scale (NRS).
Time frame: 6 months
Change from baseline to 3 and 6 months in the FIQ-Total score
Time frame: 6 months
Pain (including other measures of daily pain and responder analyses);
Time frame: 6 months
Function (including sub-scales of the FIQ, responder analyses of FIQ and SF-36);
Time frame: 6 months
Global efficacy measures PGIC);
Time frame: 6 months
Sleep (MOS);
Time frame: 6 months
Work productivity;
Time frame: 6 months
Depression (HADS)
Time frame: 6 months
Safety (vital signs, ECG, laboratory, suicidal ideation)
Time frame: 6 months
No study locations are listed for this record.
Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
Started May 2009 (actual). Primary completion is estimated for May 2010, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esreboxetine